Investor Presentation
GERRESHEIMER
Robust Core Business: Organic Growth Despite Covid-19
Q3 2020 Divisions
EUR m
P&D
PPG
GAT
193.7
193.8
Organic
growth
+4.3%
52.1
Organic
growth
+13.5%
45.7
Q3 2020
Q3 2019
Revenues
Q3 2019
Q3 2020
Adj. EBITDA
Organic
growth
-0.5%
31.9
Organic
growth
+3.5%
159.2
30.1
155.8
Q3 2019
Q3 2020
Q3 2019
Q3 2020
Revenues
Adj. EBITDA
6.3
1.8
Q3 2019
Q3 2020
0.6
-2.7
Q3 2019
Q3 2020
Revenues
13.10.2020
Investor Presentation
Adj. EBITDA
Strong growth in PPP and syringes, short-term
phasing effects in MDS
Margin improvement to 26.9% on the back of
organic adj. EBITDA growth of 13.5%
Negative Covid-19 one-time hit of around
EUR 6m in the cosmetics business
- Organic revenue growth of +5% disregarding the
cosmetic business
Margin improvement to 20.5% on the back of
organic adj. EBITDA growth of 3.5%
- Advanced Technologies as innovation driver and
long-term investment case
Change of revenue model: From contract
developer for PharmaCo to a revenue sharing
partner of PharmaCo
21
21View entire presentation